DCAT Value Chain Insights’ Production to Prescription

In this podcast we feature DCAT Value Chain Insights’ Top 10 Watch List for Biologics and Biomanufacturing.  For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Vaccines: the race for a vaccine against the novel coronavirus. Vaccine manufacturing: technology and scale-up. Biologic-based antivirals against the novel coronavirus. Head of the class: the top-sell...

What measures are being taken by European Union authorities to mitigate potential shortages stemming from supply-chain and manufacturing disruptions?  In this podcast we feature an article that outlines the guidance issued by EU authorities to provide flexibility in sourcing for crucial medicines for the treatment of COVID-19. For the text version of this article visit dcatvci.org . Key topics: (s...

What impact is COVID-19 having on pharmaceutical supply chains? In this podcast, we feature an article that reports on the concerns raised by industry groups, including reduced availability of international air transportation and increasing costs for shipping medicines into the US. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Industry groups weigh in o...

In this podcast, we feature an article that looks at the Indian government’s $1.3-billion multi-year plan to increase domestic production of key starting materials and active pharmaceutical ingredients and its potential impact on global supply chains. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) India and pharmaceuticals: short term India and pharmaceu...

What does the global nature of the pharmaceutical supply chain mean for US policy? In this podcast, we feature an article that looks at proposals from members of Congress and the federal government to incentivize domestic drug manufacturing in the US. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Global pharmaceutical supply chains Proposals for encoura...

What are the new blockbuster medicines to watch? In this podcast we feature an article that examines the eleven medicines projected to enter the market in 2020 and achieve blockbuster status by 2024, according to a recent analysis by Clarivate Analytics’ Cortellis Forecast Team. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Blockbuster watch: Big Pharma...

Over the past several years, orphan drugs have accounted for more than 40% of new drug approvals by the FDA.  In this podcast, we showcase an article that explores whether they are producing the revenue gains pharma companies are seeking or if they are too niche? For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Inside new drug approvals and drug-developmen...

To what extent do emerging pharma companies contribute to the pharmaceutical industry’s pipeline and new product growth? In this podcast, we showcase an article examining a recent report by IQVIA that analyzes emerging bio pharma companies’ contribution to innovation. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Inside the numbers Inside emerging bioph...

The conditions are favorable for another strong year of performance for CDMOs. In this podcast, we showcase an article written by Jim Miller, Consultant and Content Advisor at DCAT, that examines industry fundamentals and an outlook for pharma outsourcing in 2020. For the text version of this article go to dcatvci.org . Key topics: (see Chapter Markers) Strong fundamentals but some risk    Mergers...